Top

Indian Immunologicals launches its first set of virtual medical representatives

HYDERABAD: Indian Immunologicals Ltd., the Hyderabad-based subsidiary of the National Dairy Development Board (NDDB), is at the forefront of the business process innovation, propelling the digital ecosystem through its division by launching its first set of virtual medical representatives, an alternative to facilitate physician’s interface in form of eMOz.

Traditional sales models in the pharma industry have been primarily indexed on engagement between sales representatives and physicians which has led to volume-based formulae, more sales representatives equal more visits to doctors, assuming incremental business. However, long have the industry embraced the challenge that the average time spent by physicians with a sales rep has seen a drastic downturn owing to various intersecting factors. The COVID-19 pandemic caused further restrictions that significantly curtailed reps’ access to physicians.

eMOZ is a cutting edge and promising tool for information sharing, as it has inbuilt capabilities to provide constant update on specific needs of the physicians, thus fostering meaningful, tangible, and enduring gains. eMOz will enable complete stakeholder management on a virtual platform by providing detailed access to products and services. This will reduce several entry barriers while enhancing the cost efficiency. eMOz will eventually be acquiring AI avatars of sales representatives to interact and assist physicians in one of its kind experiences.

eMOz will provide credible solutions digitally for better patient care by offering greater convenience to the physicians and saving their precious time.

Speaking on the launch of eMOz, Dr. K. Anand Kumar, Managing Director of IIL said “This generation of healthcare professionals are quite open for digital channels of communication, and we envision to provide an engaging digital experience to our customers while focusing foremost on covering untapped markets”.

( Source : Deccan Chronicle. )
Next Story